Get the Stockscreener App
2.71
3.90%
-0.11
After Hours:
2.70
-0.010
-0.37%
Biovie Inc stock is traded at $2.71, with a volume of 1.17M.
It is down -3.90% in the last 24 hours and down -5.24% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$2.82
Open:
$2.85
24h Volume:
1.17M
Relative Volume:
0.21
Market Cap:
$47.71M
Revenue:
-
Net Income/Loss:
$-43.27M
P/E Ratio:
-1.7597
EPS:
-1.54
Net Cash Flow:
$-41.11M
1W Performance:
-19.35%
1M Performance:
-5.24%
6M Performance:
-40.33%
1Y Performance:
-94.83%
1-Day Range:
$2.6701
$2.8837
1-Week Range:
$2.6701
$3.4278
52-Week Range:
$1.0404
$55.20
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
2.71 | 47.71M | 0 | -43.27M | -41.11M | -1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
Biovie Inc. to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long Covid At Theemystifying Long Covid International Conference - Marketscreener.com
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference - The Manila Times
BioVie to Present Design of Planned Phase 2 Study of - GlobeNewswire
BioVie's Long COVID Drug Trial Gets Pentagon Backing; Phase 2 Study to Include 200 Patients | BIVI Stock News - StockTitan
BioVie shareholders approve board nominees and equity plan expansion By Investing.com - Investing.com Canada
BioVie shareholders approve board nominees and equity plan expansion - Investing.com India
BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded - GlobeNewswire
BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded - The Manila Times
BioVie Raises Capital Through Direct Stock Offering - MSN
BioVie Inc. Announces Closing of Registered Direct Offering - GlobeNewswire
BioVie Raises $3.24 Million in Direct Offering - TipRanks
BioVie sets price for $3.2 million stock offering By Investing.com - Investing.com Australia
BioVie prices stock offering at $2.83 per share By Investing.com - Investing.com Canada
BIVIBioVie, Inc. Latest Stock News & Market Updates - StockTitan
BioVie prices stock offering at $2.83 per share - Investing.com
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
BioVie sets price for $3.2 million stock offering - Investing.com India
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Short Interest in BioVie Inc. (NASDAQ:BIVI) Decreases By 51.0% - MarketBeat
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Carson City, Nevada, October 23, 2024 — BioVie Inc. (NASDAQ: BIVI), a clinical-stage company focused on developing innovative drug therapies for ch - Defense World
BioVie Raises $6 Million in Strategic Funding - TipRanks
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement - StockTitan
BioVie Announces $6 Million Stock Offering and Placement - TipRanks
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BioVie announces $6 million stock offering and warrants By Investing.com - Investing.com Australia
BioVie announces $6 million stock offering and warrants - Investing.com India
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - The Manila Times
BioVie 2.667M share registered direct offering priced at $2.25 - TipRanks
BioVie Inc. Announces Pricing of Registered Direct Offering - GlobeNewswire
BioVie stock dips after pricing offering to raise $6.66M - MSN
BioVie Announces Stock Offering and Private Placement - Yahoo Finance
Join BioVie's Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024 - The Manila Times
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024 - GlobeNewswire
BioVie announces $6.7 million direct stock offering - Investing.com India
BioVie Secures $6.66 Million Through Direct Offering - TipRanks
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
3 Penny Stocks to Watch Now, 10/22/24 - TipRanks
BioVie stock dips after pricing offering to raise $6.66M (NASDAQ:BIVI) - Seeking Alpha
BioVie announces $6.7 million direct stock offering By Investing.com - Investing.com Australia
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):